Catherine Coste
CIK 1821432 · last filed 2026-02-26
Catherine Coste is a corporate insider who has filed 12 SEC Form 4 insider transactions across 4 companies since 2020. The most recent filing, for BLFS, was dated Feb 26, 2026. Across all open-market trades the lifetime net is +$56.1K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $644.7K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$644.7K
4
12
$56.1K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BLFS | Director | 13,871 | $26.10 | $362.0K | $0 | 2 | 2026-02-26 |
| BMRA | Director | 137,890 | $2.05 | $282.7K | $56.1K | 7 | 2024-12-17 |
| Renalytix plc (RNLX) Delisted | Director | — | $0.21 | — | $0 | 2 | 2023-11-22 |
| UTRS | Director | 129,579 | $0.00 | $13 | $0 | 1 | 2022-06-14 |
Recent Filings
12 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-26 | BLFS | Grant (A) | +8,170 | $0 | EDGAR |
| 2025-03-20 | BLFS | Grant (A) | +5,701 | $0 | EDGAR |
| 2024-12-17 | BMRA | Grant (A) | +85,000 | $26.4K | EDGAR |
| 2023-12-14 | BMRA | Grant (A) | — | $0 | EDGAR |
| 2023-12-11 | BMRA | Grant (A) | — | $0 | EDGAR |
| 2023-11-22 | Renalytix plc (RNLX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-07-07 | Renalytix plc (RNLX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-01-30 | BMRA | Buy (P) | +2,190 | $6.5K | EDGAR |
| 2022-06-14 | UTRS | Grant (A) | +49,792 | $120.0K | EDGAR |
| 2021-12-10 | BMRA | Grant (A) | — | $0 | EDGAR |